Llanos‐Cuentas 2001.

Methods	Randomized controlled trial Length of follow up: 28 d Generation of allocation sequence: unclear Allocation concealment: unclear Blinding: none Inclusion of all randomized participants in the final analysis: 39 analysed/43 randomized (91%)
Participants	Number enrolled: 43 Age range: 15 to 65 years Gender: male and female Inclusion criteria: age 12 to 65 years; presence of acute uncomplicated falciparum malaria; lifelong residents of the study area; parasitaemia between 1000 and 200,000 parasites/µL Exclusion criteria: severe malaria; presence of mixed infections with other Plasmodium species; presence of concomitant disease; inability to take oral treatment; pregnancy; breastfeeding mother
Interventions	1. Atovaquone plus proguanil (1000 mg atovaquone, 400 mg proguanil over 3 d) 2. Chloroquine (1500 mg over 3 d) 3. Sulfadoxine‐pyrimethamine (1500 mg sulfadoxine and 75 mg pyrimethamine)
Outcomes	1. 28‐d cure rate 2. Parasite clearance time 3. Fever clearance time 4. Adverse events
Notes	Location: Peru Drug resistance: high for chloroquine